Analyst firms · Morgan Stanley · AZN

Morgan Stanley AZN price target and rating history

AstraZeneca PLC (AZN) · Health Care

Morgan Stanley rates AstraZeneca PLC (AZN) Overweight with a $85 price target, as of its latest action on Feb 12, 2025. It has published 4 rating actions on AZN since September 2022, including 1 upgrade and 1 downgrade.

Current rating
Overweight
Price target
$85
Median target, all firms
Too few
Actions on AZN
4

Every Morgan Stanley rating on AZN

How other firms rate AZN

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Deutsche BankHoldSep 15, 2026
RBC Capital MarketsOutperformSep 9, 2026
HSBCHoldJul 13, 2026
CitigroupBuyJan 27, 2026

Questions about Morgan Stanley and AZN

What is Morgan Stanley's price target for AZN?
Morgan Stanley's latest stated price target for AstraZeneca PLC (AZN) is $85, from its action on Jan 23, 2024.
What is Morgan Stanley's rating on AZN?
Morgan Stanley rates AZN Overweight, a bullish rating, as of Feb 12, 2025.
When did Morgan Stanley last change its view on AZN?
On Feb 12, 2025, Morgan Stanley starts coverage at Overweight.

More AZN rating histories

All Morgan Stanley ratingsAZN news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.